Mscripts launches Web Pharmacy
SAN FRANCISCO — Mobile pharmacy technology company Mscripts has launched Web Pharmacy, which will allow pharmacies to offer patients an integrated and branded web and mobile environment to manage their health and prescription needs, the company said Tuesday.
The system provides customers with a unified, omnichannel experience for text, phone and web interactions and provides many of the same features available with Mscripts’ Mobile Pharmacy, including one-click refill, consolidated view of medications, pharmacy locator and transfer of prescriptions. Patients also can create medical expense reports, and sort and search capabilities.
"The addition of Mscripts Web Pharmacy allows pharmacies to satisfy the needs of a broad consumer base — some may prefer using the Web, while others their mobile phone, or a combination of both," Mscripts CEO Mark Cullen said. "Mscripts’ Web Pharmacy employs an intuitive interface customized with each customer’s brand, creating new opportunities for improved interactions, adherence and refill rates."
Macmillan Children’s Publishing launches preschool line for BTS season
NEW YORK — Last month, Schoolies, a line of preschool books and flash cards published by Priddy Books, a division of Macmillan Children’s Publishing Group, launched into mass, book, specialty and online retailers across the country in time for the back-to-school seson. Now, the company is set to launch nine new titles for spring 2014.
The Schoolies publishing program expansion continues with nine new titles releasing next spring, including a coloring activity book, two sticker activity books, four 8×8 readers — "Time for Recess," "The Talent Show," "The Field Trip" and "The School Fair" — and "My Fun School Set" that includes five books, crayons and more. Initially introduced through a successful mobile app, Schoolies’ inaugural book line features Spencer the Owl and his friends as they prepare for their first day of school, make new friends and learn their ABCs and 123s.
"We have been really pleased by the positive response to Schoolies," said Roger Priddy, publisher of Priddy Books. "While we saw the potential of combining Ellen Crimi-Trent’s fun collection of characters, along with our Priddy Books approach to early learning, the initial sell-in and sell-through results have been great and confirm the broad appeal of this brand. Schoolies is a classic combination of great children’s book characters and essential first learning with all the potential for a strong publishing program for many years to come. "
"The talented team at Priddy, along with their high standards for product quality and creativity, have been integral in evolving Schoolies into the educational preschool brand that I have long aspired for it to become," said Schoolies creator, Ellen Crimi-Trent. "The books are just the beginning, as Schoolies really lends itself to many different products and media platforms. The success to date, along with Priddy’s continued commitment to expand the publishing program, is ideal to seed the brand, introduce the characters, and make it a perennial favorite among teachers, parents and preschoolers in the United States and around the world."
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.
Hospira reports mostly flat sales in Q2 2013
LAKE FOREST, Ill. — Hospira posted sales of $1 billion during second quarter 2013, a 0.7% decrease compared with second quarter 2012, the generic drug maker said.
Hospira, which specializes in making generic injectables, also posted $318.7 million gross profit, a 12.4% increase over second quarter 2012’s $283.5 million.
"Results for the second quarter were in line with our expectations," CEO F. Michael Ball said. "In addition, it was a quarter of several milestone achievements for Hospira, such as the positive opine from the European Medicines Agency on our biosimilar infliximab, Inflectra, and the U.S. launch of the new premix versions of our branded sedation agent, Precedex."
Infliximab is a biosimilar version of Johnson & Johnson’s Remicade, used to treat autoimmune disorders like arthritis, psoriasis and inflammatory bowel disease.